nucleophilic carbon-centered radicals is furtheron developed by the following new achievements: i) utilization of the redoc system in several solvents; ii) utilization of benzoyl peroxide in alcohols; iii) carbamoylation by HCONH2 and H2O2 in the presence of catalytic amounts of Fe(II). These systems allow to obtain either substitution till now tried without success or reactions of industrial interest.
下列新成果进一步发展了质子化杂芳族碱基被亲核碳中心自由基直接取代的综合兴趣:ii)酒精中过氧化苯甲酰的利用;iii)在催化量的Fe(II)存在下通过HCONH 2和H 2 O 2进行氨基甲酰基化。这些系统允许获得直到现在为止一直没有成功的替代方案,或者获得工业利益的反应。极性效应在确定反应性,选择性和合成应用方面起主要作用;特别强调了吡啶基类型的强亲核中间基团在重新麦芽糖化步骤中的作用。
DNA labeling reagents, acridinium-9-carboxamide derivatives and process of preparing DNA labeling compounds
申请人:AsiaGEN Corporation
公开号:US20040219538A1
公开(公告)日:2004-11-04
The present invention relates to DNA labeling reagents comprising a furocoumarin derivative and a detectable group with or without bound via a binding enhancer, and acridinium-9-carboxamide derivatives for use as chemiluminescent labels. The present invention also relates to a process of preparing DNA labeling compound.
[EN] AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS<br/>[FR] MODULATEURS DE LXR À BASE D'AMINE OU DE (THIO) AMIDE
申请人:PHENEX FXR GMBH
公开号:WO2019016269A1
公开(公告)日:2019-01-24
The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXRα and/or LXRβ) and act preferably as inverse agonists of LXR.
本发明涉及公式(I)的衍生物,其结合到肝X受体(LXRα和/或LXRβ),并且作为LXR的拮抗剂。
[EN] BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION<br/>[FR] TRAITEMENT MÉDICAMENTEUX ET PANEL DE BIOMARQUEURS CIBLANT DES MALADIES DUES À L'ONTOLOGIE MULTIFACTORIELLE DE L'INTERRUPTION DE LA GLYCOCALYX
申请人:ARTEREZ INC
公开号:WO2021062298A1
公开(公告)日:2021-04-01
The present disclosure provides biomarkers useful as companion diagnostics for detecting glycocalyx-based disease that is amenable to treatment using compounds designed for improving the condition of the glycocalyx and/or reducing inflammation and/or oxidative damage, as well as related compositions, kits, and methods.
Methods of assaying for (i) a pterin by immunoassay employing a pterin as capture agent, (ii) neopterin by chemiluminescent microparticle immunoassay (CMIA) employing an anti-neopterin antibody (Ab) as capture agent, (iii) neopterin by an immunoassay (IA) employing an acridinium (Acr)-labeled anti-neopterin Ab as conjugate, and (iv) neopterin by an IA employing Acr-labeled neopterin as tracer; an Acr-labeled anti-neopterin Ab; a conjugate/complex comprising anti-neopterin Ab and a carrier scaffold; a conjugated pterin; a conjugate comprising an Acr-labeled pterin and a carrier scaffold; an immunogen comprising neopterin and a carrier protein; a conjugate comprising such an immunogen and an Acr compound; an immunogen comprising a carrier protein and a neopterin hapten; a conjugate comprising such an immunogen and an Acr compound; a kit for assaying a pterin comprising a pterin as a capture agent and instructions for IA; and a kit for assaying neopterin comprising an anti-neopterin Ab as a capture agent and instructions for CMIA, neopterin comprising an Acr-labeled anti-neopterin Ab as a conjugate and instructions for IA, or Acr-labeled neopterin as a tracer and instructions for IA.